The present invention provides a topical composition for application to a keratinous tissue comprising a cosmetically or pharmaceutically acceptable carrier; one or more selected from potassium, zinc, calcium, rubidium disposed in the cosmetically or pharmaceutically acceptable carrier; and one or more cannabis extracts disposed in the cosmetically or pharmaceutically acceptable carrier.

Long-lasting biodegradable subcutaneous implant with prolonged release of pharmacologically active substance pre-concentrated in polymer for the treatment of epilepsy using from 10 to 1000 mg essential oil extracted from Cannabis sativa and/or Cannabis indica (full or broad spectrum), 10 to 500 mg natural or synthetic tetrahydrocannabidiol (THC) isolate, 10 to 500 mg natural or synthetic cannabidiol (CBD) isolate, proportional combination of broad spectrum essential oil and CBD isolate, proportional combination of full spectrum essential oil and natural or synthetic CBD isolate, or proportional combination of natural or synthetic THC isolate and CBD isolate in polymeric matrix for adjuvant treatment of epilepsy, chronic pain and anxiety.

Disclosed embodiments include systems and methods for obtaining desired organic compounds from harvested biomass. Some examples include an extraction vessel and a distillery system, where the extraction vessel is configured to wash harvested biomass with a process solvent to obtain a liquid extract, and where the distillery system is configured to distill the extract to separate the process solvent from the extract and obtain a distillate from the extract. Some embodiments additionally include a speedloader configured to load harvested biomass into the extraction vessel and a discharge gantry configured to remove processed biomass from the extraction vessel. In some embodiments, the extraction vessel, distillery system, speedloader, and discharge gantry are mobile and can be deployed in field at a harvest location.

A pharmaceutical composition comprises Vijaya ranges from 55-65% of the weight of the composition, Vanshlochan ranges from 45-55% of the weight of the composition, Ashwagandha in the range of 10-20% by w/w and one or more of a pharmaceutically accepted excipients. The pharmaceutical composition is provided for managing dysmenorrhea.

Provided is a composition comprising multiple cannabis storage cavities and/or multiple cannabis secretory cells, wherein at least 20% of said storage cavities and/or at least 20% of said secretory cells are intact and wherein each of said intact storage cavities and/or each of said intact secretory cells contains therein at least one cannabinoid. Further provided are products comprising the composition and methods of use thereof.

Methods of manufacturing a cannabinoid product can involve extracting from raw cannabis plant material an extract including cannabinoids and terpenes; separating the extract into a cannabinoid rich fraction and a terpene rich fraction; subjecting the terpene rich fraction to heating in a microwave oven thereby to distil terpene components from the terpene rich fraction; collecting the terpene components. In some embodiments, at least one of the terpene components can be recombined with at least one cannabinoid from the cannabinoid rich fraction. Preferably, the heating step is carried out while subjecting the terpene rich fraction to a vacuum. The cannabinoid rich fraction is processed by crystallisation and recrystallisation to produce a purified acidic cannabinoid component, wherein the purified acidic cannabinoid component can remain carboxylated or be decarboxylated is combined with said at least one terpene component. The recombined cannabinoid product can exhibit characteristics closer to those of the original plant.

Extractive process for obtaining an oil based on phytocannabinoids, said oil being selected from olive oil, extra virgin olive oil, seed oil in general, hemp seed oil and combinations thereof, said process using as biomass starting with dried flowers and leaves of the Cannabis plant, said process providing for the implementation in sequence of the following steps: kneading, extraction, decanting/separation, filtration; said process being characterized in that it jointly uses as extraction solvent water as polar solvent and an oil selected from said olive oil, extra virgin olive oil and hemp seed oil, seed oil in general and combinations thereof such as apolar solvent, said starting biomass including substances such as CBD, CBDA, CBG, CBGA, THC, THCA, THCV, THCVA, terpenes, fat-soluble cannabinoids.

Described is a method of reducing or eliminating chlorophyll content in a plant extract, while retaining certain other active components of said extract, by exposing said plant extract to a UV-C light source. Also described are extracts having lower levels of chlorophyll while retaining levels of certain other active components, such as cannabinoids and terpenes.

Disclosed herein is a method of modifying a plant material, a product produced by the method, and a system to implement the method.

The present invention relates to compositions comprising cannabinoids. The present invention also relates to pharmaceutical compositions, dosage forms and methods of treating neurological disorders by administering the composition to a patient in need thereof.